Ken Griffin Karyopharm Therapeutics Inc. Put Options Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2024 Feb 14, 2025	SELL	$0.6 - $0.99 $2,520 - $4,158	-4,200 Reduced 11.51%	32,300 $21,000
Q3 2024 Nov 14, 2024	BUY	$0.7 - $1.06 $8,260 - $12,508	11,800 Added 47.77%	36,500 $30,000
Q2 2024 Aug 14, 2024	BUY	$0.87 - $1.58 $3,132 - $5,688	3,600 Added 17.06%	24,700 $21,000
Q1 2024 May 15, 2024	BUY	$0.72 - $1.66 $9,864 - $22,742	13,700 Added 185.14%	21,100 $31,000
Q4 2023 Feb 14, 2024	SELL	$0.68 - $1.31 $2,924 - $5,633	-4,300 Reduced 36.75%	7,400 $6,000
Q3 2023 Nov 14, 2023	SELL	$1.14 - $1.81 $23,711 - $37,648	-20,800 Reduced 64.0%	11,700 $15,000
Q2 2023 Aug 14, 2023	BUY	$1.79 - $4.59 $1,432 - $3,672	800 Added 2.52%	32,500 $58,000
Q1 2023 May 15, 2023	SELL	$2.84 - $3.92 $154,496 - $213,248	-54,400 Reduced 63.18%	31,700 $123,000
Q4 2022 Feb 14, 2023	BUY	$2.48 - $5.93 $19,096 - $45,661	7,700 Added 9.82%	86,100 $292,000
Q3 2022 Nov 14, 2022	SELL	$4.08 - $5.82 $25,704 - $36,666	-6,300 Reduced 7.44%	78,400 $428,000

4.39M

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $321M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.